Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization

J Med Chem. 2011 Jul 28;54(14):5237-44. doi: 10.1021/jm200701g. Epub 2011 Jul 1.

Abstract

Sequence analysis of eosinophil cationic protein (ECP), a ribonuclease of broad antimicrobial activity, allowed identification of residues 1-45 as the antimicrobial domain. We have further dissected ECP(1-45) with a view to defining the minimal requirements for antimicrobial activity. Structure-based downsizing has focused on both α-helices of ECP(1-45) and yielded analogues with substantial potency against Gram-negative and -positive strains. Analogues ECP(8-36) and ECP(6-17)-Ahx-(23-36) (Ahx, 6-aminohexanoic acid) involve 36% and 40% size reduction relative to (1-45), respectively, and display a remarkably ECP-like antimicrobial profile. Both retain segments required for self-aggregation and lipolysaccharide binding, as well as the bacterial agglutination ability of parent ECP. Analogue (6-17)-Ahx-(23-36), in particular, is shown by NMR to preserve the helical traits of the native 8-16 (α1) and 33-36 (α2) regions and can be proposed as the minimal structure capable of reproducing the activity of the entire protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agglutination
  • Amino Acid Sequence
  • Anti-Bacterial Agents / chemistry*
  • Anti-Bacterial Agents / pharmacology
  • Eosinophil Cationic Protein / chemistry*
  • Gram-Negative Bacteria / drug effects
  • Gram-Positive Bacteria / drug effects
  • Hemolysis
  • Humans
  • Lipopolysaccharides / chemistry
  • Liposomes
  • Magnetic Resonance Spectroscopy
  • Micelles
  • Microbial Sensitivity Tests
  • Models, Molecular
  • Molecular Sequence Data
  • Peptides / chemical synthesis
  • Peptides / chemistry*
  • Peptides / pharmacology
  • Protein Structure, Secondary
  • Structure-Activity Relationship

Substances

  • Anti-Bacterial Agents
  • Lipopolysaccharides
  • Liposomes
  • Micelles
  • Peptides
  • Eosinophil Cationic Protein